论文部分内容阅读
目的 探讨洛沙坦对糖尿病大鼠肾脏肥大的影响及其与肾小球周期素激酶抑制剂P2 7水平的关系。 方法 腹腔注射链脲佐菌素建立糖尿病 (DM )模型并分别给予生理盐水、洛沙坦1mg·kg-1·d-1或 2mg·kg-1·d-1灌胃 8周。Western杂交方法测定肾小球裂解液P2 7蛋白水平 ,ELISA方法测定肾小球裂解液细胞外基质 (ECM )蛋白 (Ⅳ型胶原及纤维连接蛋白 )和尿白蛋白 ,采用图象分析系统测定肾小球面积。 结果 DM 8周大鼠肾重 /体重比例增高 ,肾小球面积增大 ,肾小球ECM蛋白水平增加 ,2 4h尿白蛋白排泄增多 ,同时肾小球P2 7水平增高。洛沙坦降低DM大鼠肾重 /体重比例、肾小球面积及肾小球ECM蛋白水平 ,减少 2 4h尿白蛋白排泄 ,降低肾小球P2 7水平。洛沙坦的上述作用随剂量的增加而增强。洛沙坦不改变DM大鼠血糖水平。 结论 洛沙坦可减轻DM大鼠肾小球肥大程度 ,此作用可能与洛沙坦降低DM大鼠肾小球P2 7水平有关
Objective To investigate the effects of losartan on renal hypertrophy in diabetic rats and its relationship with the P2 7 level of glomerular cyclinskin kinase inhibitor. Methods Diabetic model was established by intraperitoneal injection of streptozotocin (STZ) and was given normal saline, losartan 1 mg · kg-1 · d-1 or 2 mg · kg-1 · d-1 for 8 weeks respectively. Western blotting was used to determine the level of P2 7 protein in glomerular lysate. The levels of extracellular matrix (ECM) protein (type IV collagen and fibronectin) and urinary albumin in glomerular lysate were detected by ELISA. Small ball area. Results The ratio of renal weight to body weight increased, the area of glomerulus increased, the level of glomerular ECM increased, the excretion of urinary albumin increased at 24 h, and the level of glomerular P2 7 increased at the same time. Losartan decreased renal weight / body weight ratio, glomerular area and glomerular ECM protein level in DM rats, decreased urinary albumin excretion by 24 hours, and decreased glomerular P2 7 level. The above effects of losartan increase with dose. Losartan does not change blood glucose levels in DM rats. Conclusion Losartan can reduce the degree of glomerular hypertrophy in DM rats, which may be related to the decrease of glomerular P2 7 in DM rats